Heart injury in juvenile systemic sclerodermy (clinical case)
Keywords:juvenile systemic scleroderma, dilated cardiomyopathy, children
Juvenile systemic sclerosis (JSS) has many clinical manifestations that differ from adults. Early diagnosis is problematic. The course of the disease and the severity of the prognosis depend on the involvement of internal organs in the process, first of all, the heart, lungs, kidneys. Cardiac pathology is a frequent and prognostically unfavorable target of the scleroderma process in adults, but it is rarely diagnosed in children. The aim of the work was to study the features of the clinical manifestations of systemic sclerosis in a child with severe heart disease. A polymorphism of the clinical symptoms of severe heart damage with the development of dilated cardiomyopathy in a one-year-old child with systemic sclerosis is presented. The features of the case are the early debut of systemic sclerosis in a child with a burdened hereditary history of autoimmune pathology (psoriasis in the father and grandmother), rapid progression of the autoimmune process, severe heart damage by the type of non-compact (dilated) cardiomyopathy, positive clinical dynamics when using pathogenetic therapy. Early detection of cardiovascular lesions using modern diagnostic methods, timely implementation of adequate therapy in a multidisciplinary team and regular cardiovascular screening can improve the prognosis, quality of life and reduce mortality.
Porter A, Mirizio E, Fritzler MJ, Brown R, Choi M, Schollaert-Fitch K, et al. Autoantibody testing in pediatric localized scleroderma (LS). Arthritis Rheumatol. 2018;70 (suppl 10). doi: https://doi.org/10.3389/fimmu.2019.00908
Wu EY, Li SC, Torok KS, Virkud Y, Fuhlbrigge R, Rabinovich CE. Baseline description of the juvenile localized scleroderma subgroup from the childhood arthritis and rheumatology research alliance legacy registry. ACR Open Rheumatol In press. 2019;1:119-24. doi: https://doi.org/10.1002/acr2.1019
Stasiulis E, Gladstone B, Boydell K, et al. Children with facial morphoea managing everyday life: a qualitative study. Br J Dermatol. 2018;179:353. doi: https://doi.org/10.1111/bjd.16449
Zulian F, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019;78:1019.
Hung G, Mercurio V, Hsu S, Mathai S. Shah C. Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis. Current rheumatology reports. 2019;12:68. doi: https://doi.org/10.1007/s11926-019-0867-0
Mirizio E, Marathi A, Hershey N, Ross C, Schollaert K, Salgadgo CM, et al. Identifying the signature immune phenotypes present in pediatric localized scleroderma. J Invest Dermatol. 2018;139:715-8. doi: https://doi.org/10.1016/j.jid.2018.09.025
Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of pediatric localized scleroderma. Front Immunol. 2019;10:1-11. doi: https://doi.org/10.3389/fimmu.2019.00908
Macaubas C, Mirizio E, Schollaert-Fitch K, Mellins ED, Torok KS. Interferon gamma (IFN-γ) Subpopulations in skin homing T-cells of localized scleroderma [abstract]. Arthritis Rheumatol. 2017;69 (suppl 10). doi: https://doi.org/10.3389/fimmu.2019.00908
Kurzinski K, Zigler CK, Torok KS. Prediction of disease relapse in a cohort of juvenile localized scleroderma patients. Br J Dermatol. The British Journal of Dermatology. 2018;180(5):1183-9. doi: https://doi.org/10.1111/bjd.17312
Singhvi G, Manchanda P, Krishna Rapalli V, et al. MicroRNAs as biological regulators in skin disorders. Biomed Pharmacother. 2018;108:996-1004. doi: https://doi.org/10.2147/JPR.S221615
Li Y, Zhang J, Lei Y, et al. MicroRNA-21 in skin fibrosis: potential for diagnosis and treatment. 2017;21:633-42. doi: https://doi.org/10.1007/s40291-017-0294-8
Li SC, Li X, Pope E, Stewart K, Higgins GC, Rabinovich CE, et al. New Features for Measuring Disease Activity in Pediatric Localized Scleroderma. J Rheumatol in press. 2018;45:1680-8. doi: https://doi.org/10.3899/jrheum.171381
Schoch J, Schoch B, Davis D. Orthopedic complications of linear morphea: Implications for early interdisciplinary care. Pediatric Dermatol. 2018;35:43-6. doi: https://doi.org/10.1111/pde.13336
Chouri E, Servaas NH, Bekker CPJ, et al. Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J Autoimmun. 2018;89:162-70. doi: https://doi.org/10.1007/s00403-019-01991-0
Tenea D. The puzzle of the skin patterns. Integrative Medicine International. 2017;4:1-12. doi: https://doi.org/10.1159/000452949
How to Cite
Copyright (c) 2021 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.